Comparative effectiveness of abatacept versus TNF inhibitors in rheumatoid arthritis patients who are ACPA and shared epitope positive

Harrold, Leslie R.; Wittstock, Keith; Kelly, Sheila; Han, Xue; Zhuo, Joe; Schrader, Amy; Middaugh, Nicole; Moore, Page C.; Khaychuk, Vadim.
Adv Rheumatol ; 64: 10, 2024. tab, graf
Artículo en Inglés | LILACS-Express | ID: biblio-1550008

Documentos relacionados

  1. Comparative effectiveness of abatacept versus TNF inhibitors in rheumatoid arthritis patients who are ACPA and shared epitope positive.
  2. The double shared epitope: Its impact on clinical features and ultrasound findings in rheumatoid arthritis.
  3. Association of HLA-DRB1 locus with treatment response to abatacept or TNF inhibitors in patients with seropositive rheumatoid arthritis.
  4. HLA-DRB1 risk alleles for RA are associated with differential clinical responsiveness to abatacept and adalimumab: data from a head-to-head, randomized, single-blind study in autoantibody-positive early RA.
  5. Carriers of HLA-DRB1*04:05 have a better clinical response to abatacept in rheumatoid arthritis.
  6. Efficacy and prognostic factors of treatment retention with intravenous abatacept for rheumatoid arthritis: 24-month results from an international, prospective, real-world study.
  7. Anti-carbamylated protein antibodies as a clinical response predictor in rheumatoid arthritis patients treated with abatacept.
  8. Impact of the HLA-DRB1 shared epitope on responses to treatment with tofacitinib or abatacept in patients with rheumatoid arthritis.
  9. Subcutaneous abatacept for the treatment of rheumatoid arthritis in routine clinical practice in Germany, Austria, and Switzerland: 2-year retention and efficacy by treatment line and serostatus.
  10. Abatacept in individuals at high risk of rheumatoid arthritis (APIPPRA): a randomised, double-blind, multicentre, parallel, placebo-controlled, phase 2b clinical trial.